BLOGS WEBSITE

Michael J. Fox Foundation: Therapeutic Pipeline Program 2015

The Therapeutic Pipeline Program supports PD therapeutic development along the entire preclinical and clinical path. Although MJFF is open to any creative therapeutic strategy, ideal applications should focus on efforts to address one of the following treatment challenges:

  • Disease modifying strategies that protect or restore degenerating and/or dysfunctional neurons affected in PD (e.g., Protein folding, mitochondrial function, inflammation).
  • Strategies to alleviate disabling motor (both levodopa-responsive and non levodopa-responsive, with particular focus on gait disorders and falls) and non-motor symptoms of PD (including cognitive dysfunction, mood disorders, autonomic dysfunction and sleep disorders).
  • Strategies to alleviate complications of PD treatment including dyskinesias, impulse-control disorders, and other disabling side effects.

Funding & Duration

There is no set budget limit for proposals and applicants may request up to two years of funding for preclinical development or up to three years of funding for clinical development.

Eligibility

Applications may be submitted by:

  • U.S. and non-U.S. biotechnology/pharmaceutical companies or other for-profit entities, either publicly or privately held,
  • U.S. and non-U.S. entities, public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.

Submission Requirements & Due Dates

  • 27 May 2015 – Pre-Proposals submitted directly to Sponsor
  • Copy of Pre-Proposal forwarded to the Research Branch ASAP.
  • 29 July 2015 – full applications (by invitation only) submitted to the Research Branch for internal review.

Grants Officer: Dr Don McMaster

Email: don.mcmaster@adelaide.edu.au

Further Information

This entry was posted in Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding. Bookmark the permalink.
 

Comments are closed.